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Abstract: Background & Aims:  Non-alcoholic fatty liver disease was traditionally interpreted as a 
condition which may progress to liver-related complications. However, the increased mortality  is 
primarily a result of cardiovascular diseases. It has been suggested that fatty liver can be considered as 
the hepatic consequence of the metabolic syndrome. The aim was to describe the different clinical 
presentations of  non-alcoholic fatty liver disease on the basis of the patatin-like phospholipase 
domain-containing protein3 (PNPLA3) rs738409 gene variant.   
Methods  Fatty liver was defined by ultasonographic Hamaguchi's criteria in 211 consecutive subjects 
with non-alcoholic fatty liver disease. The rs738409 polymorphism was determined by TaqMan assays. 
Metabolic syndrome was defined according to ATPIII modified criteria.   
Results Prevalence of PNPLA3-148II, PNPLA3-148IM, and PNPLA3-148MM genotypes was 45.0%, 
40.7%, and 14.3% respectively. Prevalence of metabolic syndrome progressively increased with the 
severity of liver steatosis (from 52.5% to 65.2%, and 82.3% respectively, p<0.01).   The PNPLA3-
148MM group had significantly lower mean serum triglycerides (p<0.001), Framingham 
cardiovascular risk score (p<0.01)  and lower prevalence of metabolic syndrome (p<0.05) and its 
components. Age and HOMA-IR were positive independent predictors of metabolic syndrome, while a 
negative independent association was found between metabolic syndrome and the homozygotes 
PNPLA3 I148M variant.  
Conclusions  We suggest a lower prevalence of MetS and reduced cardiovascular risk in NAFLD 
patients with PNPLA3MM genotype.  
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results. In particular the conclusion: "We demonstrated that NAFLD does not always represent the hepatic 
manifestation of MetS since PNPLA3-I148M gene variant in our study was not associated with MetS and 
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Abstract: 
Background & Aims:  Non-alcoholic fatty liver disease was traditionally interpreted as a condition 
which may progress to liver-related complications. However, the increased mortality  is primarily a 
result of cardiovascular diseases. It has been suggested that fatty liver can be considered as the 
hepatic consequence of the metabolic syndrome. The aim was to describe the different clinical 
presentations of  non-alcoholic fatty liver disease on the basis of the patatin-like phospholipase 
domain-containing protein3 (PNPLA3) rs738409 gene variant.   
Methods  Fatty liver was defined by ultasonographic Hamaguchi’s criteria in 211 consecutive 
subjects with non-alcoholic fatty liver disease. The rs738409 polymorphism was determined by 
TaqMan assays. Metabolic syndrome was defined according to ATPIII modified criteria.   
Results Prevalence of PNPLA3-148II, PNPLA3-148IM, and PNPLA3-148MM genotypes was 
45.0%, 40.7%, and 14.3% respectively. Prevalence of metabolic syndrome progressively increased 
with the severity of liver steatosis (from 52.5% to 65.2%, and 82.3% respectively, p<0.01).   The 
PNPLA3-148MM group had significantly lower mean serum triglycerides (p<0.001), Framingham 
cardiovascular risk score (p<0.01)  and lower prevalence of metabolic syndrome (p<0.05) and its 
components. Age and HOMA-IR were positive independent predictors of metabolic syndrome, 
while a negative independent association was found between metabolic syndrome and the 
homozygotes PNPLA3 I148M variant.  
Conclusions  We suggest a lower prevalence of MetS and reduced cardiovascular risk in NAFLD 
patients with PNPLA3MM genotype.  
 
 
 
Keywords: Non alcoholic fatty liver disease, Metabolic Syndrome, PNPLA3. 
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Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common and emerging liver disease in 
Western countries [1,2]. Fatty liver includes a wide spectrum of histologic alterations ranging from 
simple steatosis, to non-alcoholic steatohepatitis (NASH), which is characterized by inflammation 
and fibrosis.   Moreover, NAFLD has been traditionally interpreted as a condition, which may 
eventually progress to liver related complications such as cirrhosis, liver cancer and liver mortality 
[3-5]. 
However, the pathogenesis of NAFLD is multifactorial and many mechanisms that cause fatty liver 
infiltration, inflammation, oxidative stress and fibrosis have been proposed.  
The association of liver steatosis  with a number of common metabolic conditions and 
cardiovascular risk factors has been extensively reported. Notably, increased mortality of NAFLD 
patients is primarily a result of cardiovascular diseases and, to a lesser extent, to liver related 
diseases [6-12]. It has been suggested that fatty liver can be considered as the hepatic consequence 
of the metabolic syndrome (MetS), a cluster of metabolic disorders including central obesity, 
hyperglycemia, arterial hypertension, hypertriglyceridemia and low HDL-cholesterol. Thus, a 
strong bidirectional association between NAFLD and MetS has been proposed. Insulin resistance, 
the key feature of MetS, is considered to play a central role in the first stages of fatty liver 
infiltration [13-15].
  
However, whether insulin resistance and hyperinsulinemia are components of 
MetS promoting fatty liver or whether NAFLD itself induces chronic hyperinsulinemia by impaired 
insulin degradation is still under debate. In addition, not all subjects with MetS will develop 
NAFLD and not all subjects with NAFLD will develop MetS. 
Several lines of evidence clearly indicated that also genetic factors may predispose to NAFLD and 
among the others a variant (I148M) located at the patatin-like phospholipase domain-containing 
protein 3 (PNPLA3) gene appears to show the strongest effect. Based on the presence of  I148M 
genotype, two different clinical presentations of  NAFLD have been recently proposed [16-23]. The 
first one is  associated to the presence of common I148I allele and characterized by a high 
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prevalence of obesity and possibly high cardiovascular risk, whereas the other one is associated to 
the I148M allele presenting an higher susceptibility to more severe liver histology and liver disease 
progression.   
Aim of the study was to evaluate whether PNPLA3 gene variants may predict different clinical 
phenotypes in a large series of Italian patients with NAFLD. 
 
Materials and methods 
Study patients  
The study was performed in 211 consecutive patients referred to our metabolic outpatient clinic 
who had evidence of fatty liver disease at a liver ultrasonographic scanning (US) performed as part 
of routine clinical examination.  
To be eligible for the study, patients had to have fulfilled the following inclusion criteria: no history 
of current or past excessive alcohol drinking as defined by an average daily consumption of alcohol 
>20 g; negative tests for the presence of hepatitis B surface antigen and antibody to hepatitis C 
virus; absence of history and clinical, biochemical and US findings consistent with cirrhosis and 
other chronic liver diseases.  None of the subjects was taking amiodarone and other drugs known to 
promote fatty liver disease. Subjects underwent routine clinical and biochemical evaluation.  Waist 
circumference, height and weight were recorded and body mass index (BMI) was calculated as 
weight (Kg) divided by height (m
2
). Blood pressure was recorded following standard procedures. 
Diabetes was diagnosed according to the WHO criteria [24].  Subjects taking insulin or oral 
antidiabetic drugs were considered to have diabetes.  According to the modified criteria of the ATP 
III Expert Panel of the US National Cholesterol Education Program [25],  metabolic syndrome was 
diagnosed on the concomitant presence of at least three of the following five clinical features: waist 
circumference (central obesity) > 102 cm in men and > 88 cm in women, fasting blood glucose > 
100 mg/dl, triglycerides > 150 mg/dl, HDL-cholesterol < 40 mg/dl in men and < 50 mg/dl in 
women, arterial systolic/diastolic blood pressure  > 130 / > 85 mm/Hg. A metabolic score was 
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calculated for each patient based on the number of the discrete components of MS identified. 
Cardiovascular risk was expressed as Framingham score determined by using the National 
Cholesterol Education Program (NCEP) calculator, available on-line at 
http://hp2010.nhlbihin.net/atpiii/calculator.asp 
Written informed consent was obtained from all patients before the study. The study was approved 
by the hospital Ethics Committee and conforms to the ethical guidelines of the 1975 Declaration of 
Helsinki.  
 
Laboratory measurements  
Serum total cholesterol, HDL-cholesterol and triglycerides were measured by an Olympus AN 560 
apparatus using an enzymatic colorimetric method. LDL-cholesterol levels were calculated 
according to the Friedwald formula. Plasma insulin levels were assayed by commercially available 
radioimmunoassay. The homeostasis model of insulin resistance (HOMA-IR), based on serum 
fasting glucose and insulin levels, was used as a measure of IR [26]. 
Adiponectin (APN) serum levels were measured with a commercial immunoassay (Tema Ricerca, 
Italy). Intra-assay and inter-assay coefficients of variation were 6 and 8%, respectively.  Serum 
levels of Cytokeratin 18-M30 were measured as marker of liver damage with a commercial 
immunoassay (Tema Ricerca, Italy) and expressed as mlU/ml. Intra-assay and inter-assay 
coefficients were 6% and 7% respectively.   
  
Ultrasonographic examination 
Liver US scanning was performed to assess the degree of steatosis. All US were performed by the 
same operator who was blinded to laboratory values using a GE Vivid S6 apparatus equipped with a 
convex 3,5 MHz probe. Liver steatosis was defined according to Hamaguchi criteria based on the 
presence of  abnormally intense, high level echoes arising from the hepatic parenchyma, liver-
kidney difference in echo amplitude, echo penetration into deep portion of the liver and clarity of 
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liver blood vessel structure [27,28]. Steatosis was assessed semi-quantitatively on a scale of 0-6: 0, 
absent; 1,2 mild; 3,4 moderate; 5,6 severe.  
 
Genetic analysis 
DNA was extracted from peripheral blood and purified by the The Wizard® Genomic DNA 
Purification Kit following the manufacturing protocol. Fluorogenic 5′-nucleotidase assays were 
developed to genotype the PNPLA3 rs738409 C to G nonsynonymous sequence variant, encoding 
I148M, in all subjects. The assay was performed using the TaqMan C7241_10 assay (Applied 
Biosystems, Foster City, CA) on ABI PRISM 7900 HT Sequence Detection Systems. (Applied 
Biosystems). The plate was run using standard condition at 95 °C for 10 min, 95 °C for 15 s then 
60 °C for 1 min for 40 cycles.  Allele frequencies were in Hardy–Weinberg equilibrium. The 
TaqMan assay was validated by direct sequencing of the SNP(rs738409) in representative samples 
of DNA on ABI PRISM 3130 XL Genetic Analyzer, and both methods gave identical results. 
 
Statistical analysis 
Statistical analysis was performed using the SPSS statistical software version 18.0 for Windows 
(SPSS, Inc., Chicago. Illinois). Student’s t-test for unpaired data was used for the comparison of 
mean values. Distribution of continuous variables was tested for normality using the Kolmogorov-
Smirnov test. Data are expressed as the mean  SD for normally distributed variables and as median 
and interquartile range for non-normally distributed data. Group comparisons were performed by 
use of analysis of variance (ANOVA) and unpaired Student’s t-test when appropriate. Non normally 
distributed variables were tested by Mann-Whitney test and Kruskall-Wallis test. Proportions and 
categorical variables were tested by the 2 –test and by the 2-tailed Fisher’s exact method when 
appropriate. All tests were two-tailed; a P value of less than 0.05 was considered to indicate 
statistically significance.   Multivariate analyses were performed using the stepwise logistic 
regression analysis testing for the dichotomous response variable presence or absence of MetS after 
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controlling for possible clinical and biochemical confounders.  The predictor variables entered in 
the different models were age, gender, PNPLA3-148MM, Hamaguchi score, HOMA-IR, serum 
lipid levels, serum ALT, adiponectin and cytokeratin-18 values, positive family history for diabetes 
and cardiovascular disease. 
  
Results 
Mean age was 54.5 + 11.9 years. Among the 211 subjects with fatty liver, US examination revealed 
mild steatosis in 40, moderate steatosis in 90 and severe steatosis in 81. Clinical and laboratory 
characteristics of subjects (mean age 54.5 + 11.9 yrs) with different severity of fatty liver according 
to Hamaguchi’s classification of steatosis are reported in Table 1. A progressive, statistically 
significant increase in the mean values of the indexes of central obesity (BMI, waist and hip 
circumferences), glucose metabolism (fasting blood glucose, insulin, HOMA-IR and glycosylated 
haemoglobin) serum alanine aminotransferase (ALT) and cytokeratine-18 was observed from the 
group with mild steatosis to the groups with moderate and severe steatosis; conversely, an opposite 
trend was observed for serum HDL cholesterol and adiponectin levels. No statistically significant 
between-group differences were observed for total and LDL cholesterol, triglycerides, aspartate 
aminotransferase (AST), -glutamyltransferase (GT), smoking, and statin use. 
The prevalence of MetS and its five clinical features defined according to ATPIII criteria is reported 
in Table 2. Prevalence of MetS progressively increased from subjects with mild steatosis to those 
with moderate and severe steatosis (from 52.5% to 65.2% and 82,3% respectively, p<0.01). 
Compared to subjects with mild steatosis, the relative risk in those with severe steatosis was 1.3 
(C.I. 1.0-1.6, p<0.02) for increased waist circumference, 1.6 (C.I. 1.2-2.2, p<0.01) for high blood 
pressure,  2.6 (C.I. 1.5-4.6, p<0.01) for high fasting glucose, 1.4 (C.I. 0.9-2.1 p=013) for high 
triglycerides and 1.9 (C.I. 1.0-3.4, p<0.05) for low HDL cholesterol. 
Clinical and biochemical variables of subjects with fatty liver according to the different PNPLA3 
genotypes are reported in Table 3. The overall prevalence of PNPLA3-148II,  PNPLA3-148IM and 
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PNPLA3-148MM genotypes in our cohort was 45.0% (n=95), 40.7% (n=86) and 14.3% (n=30) 
respectively. A progressive, statistically significant decrease of  mean serum triglycerides, 
Framingham cardiovascular risk score (from 9  (3/16.7) to 6  (2/13) and 4  (2/8.2) % respectively, 
p<0.01), MetS score and of the prevalence of MetS (from 71.6 % to 72.1 %  and 50 % respectively, 
p<0.05)  was observed from the group with II genotype to those with genotypes IM and MM. The 
different groups were comparable with respect to age, BMI, waist circumference, US Hamaguchi 
score, serum total and LDL-cholesterol, GGT and cytokeratin-18.   
Since at univariate analysis a lower prevalence of MetS was present in MM carriers, several models 
were generated by stepwise logistic analyses to assess the independent contribution of MM 
genotype for the prediction of MetS. In a stepwise logistic analysis including 10 clinical and 
biochemical covariates [Table 4], age, HOMA-IR, and the Hamaguchi score for steatosis were 
positive independent predictors of MetS, while a negative independent association was found 
between MetS and the homozygotes PNPLA3-I148M variant (overall predictive value of the model: 
R
2
=0.30). 
 
Discussion 
Our results show for the first time that PNPLA3-I148M gene variant is associated with a lower 
prevalence of MetS and reduced cardiometabolic risk in a large series of individuals with NAFLD. 
In fact,  univariate and multivariate analyses suggest that individuals carrying the PNPLA3 MM 
genotype have a lower probability of having MetS. 
Recently, the widely accepted assumption that NAFLD should be always considered the hepatic 
manifestation of  MetS has been disputed and the study of PNPLA3-I148M polymorphism has been 
proposed as a useful tool to discriminate fatty liver with and without metabolic consequences  and 
for estimating  the  risk for future cardiovascular or liver disease [18-19]. In fact, although the 
mechanisms underlining the association between PNPLA3 polymorphisms and NAFLD are still 
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unclear, the I148M polymorphism seems to be associated to increased hepatic lipid accumulation 
and more severe histological liver disease progression [17,20-22].  
Few studies have been performed to assess the different clinical phenotypes associated to PNPLA3 
polymorphism and none referring to MetS as a clinical condition diagnosed according to 
standardized criteria; all refer only to some aspects of MetS; most contain small number of patients 
and report conflicting results. 
In a recent study subjects homozygotes for the variant allele (PNPLA3-148MM) had significantly 
increased liver fat content with no insulin and triglyceride elevation, nor adipose tissue 
inflammation [16].
 
In a multi-ethnic study performed in Malaysia, where PNPLA3-I148M allele 
variation was associated with NASH susceptibility, NASH severity and the presence of fibrosis at 
liver histology, but not with simple steatosis and hypertriglyceridemia [17]. A further study 
performed in 335 individuals in Germany showed that PNPLA3-148MM genotype is strongly and 
independently associated with fatty liver but not with insulin resistance or estimates of liver injury 
[18]. In another study performed in Hispanic children and adolescents, liver fat in 148MM carriers 
was 2.7 times higher at nuclear resonance imaging than in wild type carriers and children with 
148MM genotype had significantly lower HDL-cholesterol levels [19]. Moreover, a large study 
showed that variation at PNPLA3 confers a markedly increased risk of increasingly severe 
histological features of NAFLD, without a strong effect on some components of MetS [20]. Finally, 
a meta-analysis performed on 16 studies across different populations showed a strong influence of 
PNPLA3-I148M variation not only on liver fat accumulation, but also on the susceptibility of a 
more aggressive disease, with MM carriers having a greater risk of higher necro-inflammation and 
of developing fibrosis when compared with PNPLA3-I148I homozygotes [21]. 
By contrast, in a large study performed in a normoglycaemic population of Taiwan,  PNPLA3-
148MM genotype was strongly associated with NAFLD and subjects had increased waist 
circumference and higher fasting insulin concentrations and higher HOMA-IR and ALT 
concentrations [29]. The reasons for these conflicting results are unclear and possibly depending on 
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the ethnic differences on the relative role of insulin resistance and MetS in the pathogenesis of 
NAFLD [30].
 
In our study, NAFLD patients with PNPLA3-148MM genotype had a lower prevalence of MetS, 
which may suggest a lower global cardiovascular risk in PNPLA3-148MM carriers. Notably, low 
levels of serum triglycerides mainly accounted for the lower prevalence of MetS in PNPLA3MM 
subjects. These findings were also confirmed by the lower average calculated Framingham 
cardiovascular risk score in MM homozygotes as compared to wild type carriers. 
Our results are consistent with the hypothesis that NAFLD might have two different clinical 
presentations, one associated to the common PNPLA3-I148I allele, presenting the clinical 
phenotype of MetS, insulin resistance and high cardiovascular risk, and the other, less frequent, 
associated to the PNPLA3-I148M allele, with a higher susceptibility to more severe liver histology 
and liver disease progression. Finally, our findings may also suggest that in the future genetic 
PNPLA3 screening could become an attractive novel target to identify individuals at high risk for 
cardio-metabolic diseases or for progressive liver disease. 
The decreased triglyceridaemia found in our PNPLA3-148MM carriers is consistent with the results 
of a study showing a lower VLDL secretion in the liver of PNPLA3-148MM carriers, as compared 
to the PNPLA3-148II homozygotes, with PNPLA3-148MM genotype alone explaining 46% of the 
variation in of VLDL triglyceride secretion. The Authors suggest that this might be the result of a 
reduced triglyceride hydrolysis in the adipose tissue leading to decreased VLDL synthesis and 
secretion and subsequent lipid deposition in the liver [31]. 
Our study may have some limitations. First, the study has been performed in patients recruited in a 
hospital-based setting. Second, fatty liver was assessed by US; the gold standard for the diagnosis 
of NAFLD is liver biopsy, but this is an invasive procedure with potentially serious complications 
and is therefore not acceptable without clinical indication. We acknowledge that grades of steatosis 
could have been better determined by magnetic resonance spectroscopy. However, Hamaguchi 
score showed 100% specificity and 91.7% sensitivity when compared with liver biopsy in NAFLD 
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patients [26]. A further limitation is the higher prevalence of females in PNPLA3MM group which 
may have determined the lower cardiometabolic risk, considering the weight that gender has in the 
Framingham score. Finally, the rather low number of patients in the PNPLA3MM group may also 
represent a limitation to draw definitive conclusions based on genetic polymorphism. 
 
 
Conclusions 
We suggest that NAFLD may not always represent the hepatic manifestation of MetS. In fact, in our 
study, patients with NAFLD carrying PNPLA3-I148M gene had a lower prevalence of MetS and 
lower cardiometabolic risk. Further studies are needed to confirm the possible role of PNPLA3 
polymorphisms to differentiate clinical phenotypes of NAFLD and  to discriminate NAFLD with 
possible metabolic and cardiovascular consequences from fatty liver at risk for liver related 
complications. 
 
Conflict of interests: All authors declare that they have no conflicts of interest. 
 
Learning points:  
 NAFLD does not always represent the hepatic manifestation of MetS 
 PNPLA3 I148M gene variant is associated with a lower prevalence of metabolic syndrome 
and lower cardiometabolic risk. 
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Table 1. Clinical and biochemical characteristics of subjects according to severity of non-
alcoholic fatty liver disease (NAFLD)  at ultrasonography 
 
 
NAFLD 
 
 
 
Mild   
(n=40) 
 
 
Moderate 
(n=90) 
 
Severe 
(n=81) 
 
p 
Gender (F/M) % 45.0/55.0 36.7/63.3 29.6/70.4 ns 
Age (yrs) 49.9 (14.6) 56.0 (11.5) 54.6 (10.4) ns 
BMI (kg/m2) 29.6 (5.1) 30.3 (5.3) 33.5 (5.3) <.001 
Waist circumference (cm) 103,5 (97,3/109,5) 105 (98/113) 113  (106/125) <.001 
Fasting plasma glucose (mg/dl) 92 (86/100,5) 97 (92,8/117,5) 107 (95/128,3) <.001 
Insulin (mU/l) 11,5 (7,7/15,5) 13 (9,3/17,9) 16,6 (12,5/24,5) <.001 
HbA1c (%) 5,4 (5,1/5,7) 5,6 (5,3/6,1) 6 (5,6/6,5) <.001 
HOMA IR 2.5 (1.6/3.7) 3.1 (2.2/4.7) 5.2 (3.1/7.3) <.001 
Total Cholesterol (mg/dl) 209 (41) 201 (40) 198 (40) ns 
Triglycerides (mg/dl) 132,5 (188,3/175/8) 138 (99,8/179) 152,5 (119,5/197,8) ns 
HDL cholesterol (mg/dl) 53 (43/60) 45,5 (39,8/60,3) 43 (38/51)  <.05 
LDL cholesterol (mg/dl) 125 (34) 121 (35) 118 (33) ns 
AST (UI/l) 19 (16/26,8) 21 (18/25) 22 (18/32) ns 
ALT (UI/l) 21 (17,3/34) 26 (20,8/40) 34 (24/45) <.05 
GT (UI/l) 23 (16,5/42,3) 21 (16/36) 32 (23,8/55) ns 
Cytokeratin 18 (mIU/ml) 169,5 (129,3/183,8) 176 (140/190) 180 (169,5/192,5) <.01 
Adiponectin (ng/ml) 10,3 (5,5/12) 8,8 (6/13,1) 6,0 (4,9/9,1) <.001 
Framingham cardiovascular 
risk score (%)* 
5 (1/14,5) 6 (3/13) 3 (9/14) ns 
*see Methods 
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Table 2. Prevalence of MetS and its clinical features in subjects with different 
severity of steatosis at liver ultrasonography. 
 
 NAFLD  
 
Mild 
(n=40) 
Moderate 
(n=90) 
Severe 
(n=81) 
p 
Metabolic Syndrome (%)* 52.5 65.2 82.3 <.01 
High blood pressure (%)* 55 78.9 88.6 <.001 
High waist circumference (%)* 70 75 91.1 <.01 
High fasting blood glucose (%)* 25 44.4 65 <.001 
High triglycerides  (%)* 40 44.4 55 ns 
Low HDL-cholesterol  (%)* 25 35.6 46.3 ns 
MetS Score** 3 (2/4) 3 (2/4) 4 (3/5) <.01 
 
*Defined according to ATPIII criteria; **see Methods 
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Table 3. Clinical and biochemical characteristics of subjects with different PNPLA3 
genotypes 
 
                                  PNPLA3 genotypes 
 
148II 
(95) 
148IM  
(86) 
148MM  
(30) 
p 
Gender (F/M) % 27.4/72.6 39.5/60.5 50/50 <.05* 
Metabolic Syndrome (%) 71.6 72.1 50 <.05* 
Age (yrs) 54 ± 11 54 ± 12.8 54.3 ± 12.1 ns 
Weight (kg) 92.2±18.1 89.0±16.5 89.8±16.2 ns 
BMI (kg/m2) 32.1±5.6 30.4±5.1 31.7±6.1 ns 
Waist circumference (cm) 110(103.5/118) 105(101/113.5) 106 (96.7/118.5) ns 
Fasting plasma glucose (mg/dl) 101 (92/110) 97 (92/121) 101 (87.5/128.2) ns 
Insulin (μU/ml) 14.1(10.7/20.2) 13.7(10.1/19.4) 11.6 (8.7/16.8) ns 
HOMA IR 3.6 (2.3/5.8) 3.5 (2.5/5.7) 2.8 (2.0/5.6) ns 
Total Cholesterol (mg/dl) 205 ± 41.9 198 ± 40.3 196.9 ± 34.3 ns 
Triglycerides (mg/dl) 157 (112/193) 141(107.7/185) 111.5(90.7/148.7) <.01* 
HDL cholesterol (mg/dl) 45 (39/53) 44 (38/56) 50.5 (43/61) ns 
AST (UI/l) 20 (17/25) 21 (18/31) 23 (17.7/27.7) ns 
ALT (UI/l) 26 (19/35) 30.5 (22/45) 30 (22.7/40.5) ns 
GT (UI/l) 28 (19/42) 28 (17/46) 22 (17.5/39.5) ns 
Cytokeratine 18 (mIU/ml) 180 (143/192) 180 (151.2/190) 170.5 (130/182.2) ns 
Adiponectin (ng/ml) 7.5 (5/11) 7.5 (5.5/12) 9.3 (4.9/13.1) ns 
Framingham cardiovascular 
risk score (%) 
9 (3/16.7) 6 (2/13) 4 (2/8.2) <.01* 
Hamaguchi score 4 (3/5) 4 (3/5) 4 (3/5) ns 
MetS score** 4 (2/5) 3 (2/4) 2 (1,75/4) <.01* 
 
*148MM vs 148II; **see Methods 
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Table 4. Multiple logistic analysis of independent predictors of metabolic 
syndrome in 211 subjects with non-alcoholic fatty liver disease.   
 
 B S.E. P. O.R. 95,0% C.I. for O.R. 
      Lower Upper 
  Age .062 .015 .000 1.064 1.032 1.096 
  PNPLA3.148MM -1.195 .460 .009 .303 .123 .746 
  HOMA-IR .267 .083 .001 1.306 1.110 1.538 
  Constant -3.234 .858 .000 .039   
 
Variables entered on step 1: age, gender, PNPLA3.148MM, Hamaguchi score, HOMA-IR, serum ALT 
serum adiponectin, positive family history for diabetes and cardiovascular disease. 
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Abstract: 
Background & Aims:  Non-alcoholic fatty liver disease was traditionally interpreted as a condition 
which may progress to liver-related complications. However, the increased mortality  is primarily a 
result of cardiovascular diseases. It has been suggested that fatty liver can be considered as the 
hepatic consequence of the metabolic syndrome. The aim was to describe the different clinical 
presentations of  non-alcoholic fatty liver disease on the basis of the patatin-like phospholipase 
domain-containing protein3 (PNPLA3) rs738409 gene variant.   
Methods  Fatty liver was defined by ultasonographic Hamaguchi’s criteria in 211 consecutive 
subjects with non-alcoholic fatty liver disease. The rs738409 polymorphism was determined by 
TaqMan assays. Metabolic syndrome was defined according to ATPIII modified criteria.   
Results Prevalence of PNPLA3-148II, PNPLA3-148IM, and PNPLA3-148MM genotypes was 
45.0%, 40.7%, and 14.3% respectively. Prevalence of metabolic syndrome progressively increased 
with the severity of liver steatosis (from 52.5% to 65.2%, and 82.3% respectively, p<0.01).   The 
PNPLA3-148MM group had significantly lower mean serum triglycerides (p<0.001), Framingham 
cardiovascular risk score (p<0.01)  and lower prevalence of metabolic syndrome (p<0.05) and its 
components. Age and HOMA-IR were positive independent predictors of metabolic syndrome, 
while a negative independent association was found between metabolic syndrome and the 
homozygotes PNPLA3 I148M variant.  
Conclusions  We suggest a lower prevalence of MetS and reduced cardiovascular risk in NAFLD 
patients with PNPLA3MM genotype.  
 
 
 
Keywords: Non alcoholic fatty liver disease, Metabolic Syndrome, PNPLA3. 
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Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common and emerging liver disease in 
Western countries [1,2]. Fatty liver includes a wide spectrum of histologic alterations ranging from 
simple steatosis, to non-alcoholic steatohepatitis (NASH), which is characterized by inflammation 
and fibrosis.   Moreover, NAFLD has been traditionally interpreted as a condition, which may 
eventually progress to liver related complications such as cirrhosis, liver cancer and liver mortality 
[3-5]. 
However, the pathogenesis of NAFLD is multifactorial and many mechanisms that cause fatty liver 
infiltration, inflammation, oxidative stress and fibrosis have been proposed.  
The association of liver steatosis  with a number of common metabolic conditions and 
cardiovascular risk factors has been extensively reported. Notably, increased mortality of NAFLD 
patients is primarily a result of cardiovascular diseases and, to a lesser extent, to liver related 
diseases [6-12]. It has been suggested that fatty liver can be considered as the hepatic consequence 
of the metabolic syndrome (MetS), a cluster of metabolic disorders including central obesity, 
hyperglycemia, arterial hypertension, hypertriglyceridemia and low HDL-cholesterol. Thus, a 
strong bidirectional association between NAFLD and MetS has been proposed. Insulin resistance, 
the key feature of MetS, is considered to play a central role in the first stages of fatty liver 
infiltration [13-15].
  
However, whether insulin resistance and hyperinsulinemia are components of 
MetS promoting fatty liver or whether NAFLD itself induces chronic hyperinsulinemia by impaired 
insulin degradation is still under debate. In addition, not all subjects with MetS will develop 
NAFLD and not all subjects with NAFLD will develop MetS. 
Several lines of evidence clearly indicated that also genetic factors may predispose to NAFLD and 
among the others a variant (I148M) located at the patatin-like phospholipase domain-containing 
protein 3 (PNPLA3) gene appears to show the strongest effect. Based on the presence of  I148M 
genotype, two different clinical presentations of  NAFLD have been recently proposed [16-23]. The 
first one is  associated to the presence of common I148I allele and characterized by a high 
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prevalence of obesity and possibly high cardiovascular risk, whereas the other one is associated to 
the I148M allele presenting an higher susceptibility to more severe liver histology and liver disease 
progression.   
Aim of the study was to evaluate whether PNPLA3 gene variants may predict different clinical 
phenotypes in a large series of Italian patients with NAFLD. 
 
Materials and methods 
Study patients  
The study was performed in 211 consecutive patients referred to our metabolic outpatient clinic 
who had evidence of fatty liver disease at a liver ultrasonographic scanning (US) performed as part 
of routine clinical examination.  
To be eligible for the study, patients had to have fulfilled the following inclusion criteria: no history 
of current or past excessive alcohol drinking as defined by an average daily consumption of alcohol 
>20 g; negative tests for the presence of hepatitis B surface antigen and antibody to hepatitis C 
virus; absence of history and clinical, biochemical and US findings consistent with cirrhosis and 
other chronic liver diseases.  None of the subjects was taking amiodarone and other drugs known to 
promote fatty liver disease. Subjects underwent routine clinical and biochemical evaluation.  Waist 
circumference, height and weight were recorded and body mass index (BMI) was calculated as 
weight (Kg) divided by height (m
2
). Blood pressure was recorded following standard procedures. 
Diabetes was diagnosed according to the WHO criteria [24].  Subjects taking insulin or oral 
antidiabetic drugs were considered to have diabetes.  According to the modified criteria of the ATP 
III Expert Panel of the US National Cholesterol Education Program [25],  metabolic syndrome was 
diagnosed on the concomitant presence of at least three of the following five clinical features: waist 
circumference (central obesity) > 102 cm in men and > 88 cm in women, fasting blood glucose > 
100 mg/dl, triglycerides > 150 mg/dl, HDL-cholesterol < 40 mg/dl in men and < 50 mg/dl in 
women, arterial systolic/diastolic blood pressure  > 130 / > 85 mm/Hg. A metabolic score was 
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calculated for each patient based on the number of the discrete components of MS identified. 
Cardiovascular risk was expressed as Framingham score determined by using the National 
Cholesterol Education Program (NCEP) calculator, available on-line at 
http://hp2010.nhlbihin.net/atpiii/calculator.asp 
Written informed consent was obtained from all patients before the study. The study was approved 
by the hospital Ethics Committee and conforms to the ethical guidelines of the 1975 Declaration of 
Helsinki.  
 
Laboratory measurements  
Serum total cholesterol, HDL-cholesterol and triglycerides were measured by an Olympus AN 560 
apparatus using an enzymatic colorimetric method. LDL-cholesterol levels were calculated 
according to the Friedwald formula. Plasma insulin levels were assayed by commercially available 
radioimmunoassay. The homeostasis model of insulin resistance (HOMA-IR), based on serum 
fasting glucose and insulin levels, was used as a measure of IR [26]. 
Adiponectin (APN) serum levels were measured with a commercial immunoassay (Tema Ricerca, 
Italy). Intra-assay and inter-assay coefficients of variation were 6 and 8%, respectively.  Serum 
levels of Cytokeratin 18-M30 were measured as marker of liver damage with a commercial 
immunoassay (Tema Ricerca, Italy) and expressed as mlU/ml. Intra-assay and inter-assay 
coefficients were 6% and 7% respectively.   
  
Ultrasonographic examination 
Liver US scanning was performed to assess the degree of steatosis. All US were performed by the 
same operator who was blinded to laboratory values using a GE Vivid S6 apparatus equipped with a 
convex 3,5 MHz probe. Liver steatosis was defined according to Hamaguchi criteria based on the 
presence of  abnormally intense, high level echoes arising from the hepatic parenchyma, liver-
kidney difference in echo amplitude, echo penetration into deep portion of the liver and clarity of 
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liver blood vessel structure [27,28]. Steatosis was assessed semi-quantitatively on a scale of 0-6: 0, 
absent; 1,2 mild; 3,4 moderate; 5,6 severe.  
 
Genetic analysis 
DNA was extracted from peripheral blood and purified by the The Wizard® Genomic DNA 
Purification Kit following the manufacturing protocol. Fluorogenic 5′-nucleotidase assays were 
developed to genotype the PNPLA3 rs738409 C to G nonsynonymous sequence variant, encoding 
I148M, in all subjects. The assay was performed using the TaqMan C7241_10 assay (Applied 
Biosystems, Foster City, CA) on ABI PRISM 7900 HT Sequence Detection Systems. (Applied 
Biosystems). The plate was run using standard condition at 95 °C for 10 min, 95 °C for 15 s then 
60 °C for 1 min for 40 cycles.  Allele frequencies were in Hardy–Weinberg equilibrium. The 
TaqMan assay was validated by direct sequencing of the SNP(rs738409) in representative samples 
of DNA on ABI PRISM 3130 XL Genetic Analyzer, and both methods gave identical results. 
 
Statistical analysis 
Statistical analysis was performed using the SPSS statistical software version 18.0 for Windows 
(SPSS, Inc., Chicago. Illinois). Student’s t-test for unpaired data was used for the comparison of 
mean values. Distribution of continuous variables was tested for normality using the Kolmogorov-
Smirnov test. Data are expressed as the mean  SD for normally distributed variables and as median 
and interquartile range for non-normally distributed data. Group comparisons were performed by 
use of analysis of variance (ANOVA) and unpaired Student’s t-test when appropriate. Non normally 
distributed variables were tested by Mann-Whitney test and Kruskall-Wallis test. Proportions and 
categorical variables were tested by the 2 –test and by the 2-tailed Fisher’s exact method when 
appropriate. All tests were two-tailed; a P value of less than 0.05 was considered to indicate 
statistically significance.   Multivariate analyses were performed using the stepwise logistic 
regression analysis testing for the dichotomous response variable presence or absence of MetS after 
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controlling for possible clinical and biochemical confounders.  The predictor variables entered in 
the different models were age, gender, PNPLA3-148MM, Hamaguchi score, HOMA-IR, serum 
lipid levels, serum ALT, adiponectin and cytokeratin-18 values, positive family history for diabetes 
and cardiovascular disease. 
  
Results 
Mean age was 54.5 + 11.9 years. Among the 211 subjects with fatty liver, US examination revealed 
mild steatosis in 40, moderate steatosis in 90 and severe steatosis in 81. Clinical and laboratory 
characteristics of subjects (mean age 54.5 + 11.9 yrs) with different severity of fatty liver according 
to Hamaguchi’s classification of steatosis are reported in Table 1. A progressive, statistically 
significant increase in the mean values of the indexes of central obesity (BMI, waist and hip 
circumferences), glucose metabolism (fasting blood glucose, insulin, HOMA-IR and glycosylated 
haemoglobin) serum alanine aminotransferase (ALT) and cytokeratine-18 was observed from the 
group with mild steatosis to the groups with moderate and severe steatosis; conversely, an opposite 
trend was observed for serum HDL cholesterol and adiponectin levels. No statistically significant 
between-group differences were observed for total and LDL cholesterol, triglycerides, aspartate 
aminotransferase (AST), -glutamyltransferase (GT), smoking, and statin use. 
The prevalence of MetS and its five clinical features defined according to ATPIII criteria is reported 
in Table 2. Prevalence of MetS progressively increased from subjects with mild steatosis to those 
with moderate and severe steatosis (from 52.5% to 65.2% and 82,3% respectively, p<0.01). 
Compared to subjects with mild steatosis, the relative risk in those with severe steatosis was 1.3 
(C.I. 1.0-1.6, p<0.02) for increased waist circumference, 1.6 (C.I. 1.2-2.2, p<0.01) for high blood 
pressure,  2.6 (C.I. 1.5-4.6, p<0.01) for high fasting glucose, 1.4 (C.I. 0.9-2.1 p=013) for high 
triglycerides and 1.9 (C.I. 1.0-3.4, p<0.05) for low HDL cholesterol. 
Clinical and biochemical variables of subjects with fatty liver according to the different PNPLA3 
genotypes are reported in Table 3. The overall prevalence of PNPLA3-148II,  PNPLA3-148IM and 
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PNPLA3-148MM genotypes in our cohort was 45.0% (n=95), 40.7% (n=86) and 14.3% (n=30) 
respectively. A progressive, statistically significant decrease of  mean serum triglycerides, 
Framingham cardiovascular risk score (from 9  (3/16.7) to 6  (2/13) and 4  (2/8.2) % respectively, 
p<0.01), MetS score and of the prevalence of MetS (from 71.6 % to 72.1 %  and 50 % respectively, 
p<0.05)  was observed from the group with II genotype to those with genotypes IM and MM. The 
different groups were comparable with respect to age, BMI, waist circumference, US Hamaguchi 
score, serum total and LDL-cholesterol, GGT and cytokeratin-18.   
Since at univariate analysis a lower prevalence of MetS was present in MM carriers, several models 
were generated by stepwise logistic analyses to assess the independent contribution of MM 
genotype for the prediction of MetS. In a stepwise logistic analysis including 10 clinical and 
biochemical covariates [Table 4], age, HOMA-IR, and the Hamaguchi score for steatosis were 
positive independent predictors of MetS, while a negative independent association was found 
between MetS and the homozygotes PNPLA3-I148M variant (overall predictive value of the model: 
R
2
=0.30). 
 
Discussion 
Our results show for the first time that PNPLA3-I148M gene variant is associated with a lower 
prevalence of MetS and reduced cardiometabolic risk in a large series of individuals with NAFLD. 
In fact,  univariate and multivariate analyses suggest that individuals carrying the PNPLA3 MM 
genotype have a lower probability of having MetS. 
Recently, the widely accepted assumption that NAFLD should be always considered the hepatic 
manifestation of  MetS has been disputed and the study of PNPLA3-I148M polymorphism has been 
proposed as a useful tool to discriminate fatty liver with and without metabolic consequences  and 
for estimating  the  risk for future cardiovascular or liver disease [18-19]. In fact, although the 
mechanisms underlining the association between PNPLA3 polymorphisms and NAFLD are still 
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unclear, the I148M polymorphism seems to be associated to increased hepatic lipid accumulation 
and more severe histological liver disease progression [17,20-22].  
Few studies have been performed to assess the different clinical phenotypes associated to PNPLA3 
polymorphism and none referring to MetS as a clinical condition diagnosed according to 
standardized criteria; all refer only to some aspects of MetS; most contain small number of patients 
and report conflicting results. 
In a recent study subjects homozygotes for the variant allele (PNPLA3-148MM) had significantly 
increased liver fat content with no insulin and triglyceride elevation, nor adipose tissue 
inflammation [16].
 
In a multi-ethnic study performed in Malaysia, where PNPLA3-I148M allele 
variation was associated with NASH susceptibility, NASH severity and the presence of fibrosis at 
liver histology, but not with simple steatosis and hypertriglyceridemia [17]. A further study 
performed in 335 individuals in Germany showed that PNPLA3-148MM genotype is strongly and 
independently associated with fatty liver but not with insulin resistance or estimates of liver injury 
[18]. In another study performed in Hispanic children and adolescents, liver fat in 148MM carriers 
was 2.7 times higher at nuclear resonance imaging than in wild type carriers and children with 
148MM genotype had significantly lower HDL-cholesterol levels [19]. Moreover, a large study 
showed that variation at PNPLA3 confers a markedly increased risk of increasingly severe 
histological features of NAFLD, without a strong effect on some components of MetS [20]. Finally, 
a meta-analysis performed on 16 studies across different populations showed a strong influence of 
PNPLA3-I148M variation not only on liver fat accumulation, but also on the susceptibility of a 
more aggressive disease, with MM carriers having a greater risk of higher necro-inflammation and 
of developing fibrosis when compared with PNPLA3-I148I homozygotes [21]. 
By contrast, in a large study performed in a normoglycaemic population of Taiwan,  PNPLA3-
148MM genotype was strongly associated with NAFLD and subjects had increased waist 
circumference and higher fasting insulin concentrations and higher HOMA-IR and ALT 
concentrations [29]. The reasons for these conflicting results are unclear and possibly depending on 
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the ethnic differences on the relative role of insulin resistance and MetS in the pathogenesis of 
NAFLD [30].
 
In our study, NAFLD patients with PNPLA3-148MM genotype had a lower prevalence of MetS, 
which may suggest a lower global cardiovascular risk in PNPLA3-148MM carriers. Notably, low 
levels of serum triglycerides mainly accounted for the lower prevalence of MetS in PNPLA3MM 
subjects. These findings were also confirmed by the lower average calculated Framingham 
cardiovascular risk score in MM homozygotes as compared to wild type carriers. 
Our results are consistent with the hypothesis that NAFLD might have two different clinical 
presentations, one associated to the common PNPLA3-I148I allele, presenting the clinical 
phenotype of MetS, insulin resistance and high cardiovascular risk, and the other, less frequent, 
associated to the PNPLA3-I148M allele, with a higher susceptibility to more severe liver histology 
and liver disease progression. Finally, our findings may also suggest that in the future genetic 
PNPLA3 screening could become an attractive novel target to identify individuals at high risk for 
cardio-metabolic diseases or for progressive liver disease. 
The decreased triglyceridaemia found in our PNPLA3-148MM carriers is consistent with the results 
of a study showing a lower VLDL secretion in the liver of PNPLA3-148MM carriers, as compared 
to the PNPLA3-148II homozygotes, with PNPLA3-148MM genotype alone explaining 46% of the 
variation in of VLDL triglyceride secretion. The Authors suggest that this might be the result of a 
reduced triglyceride hydrolysis in the adipose tissue leading to decreased VLDL synthesis and 
secretion and subsequent lipid deposition in the liver [31]. 
Our study may have some limitations. First, the study has been performed in patients recruited in a 
hospital-based setting. Second, fatty liver was assessed by US; the gold standard for the diagnosis 
of NAFLD is liver biopsy, but this is an invasive procedure with potentially serious complications 
and is therefore not acceptable without clinical indication. We acknowledge that grades of steatosis 
could have been better determined by magnetic resonance spectroscopy. However, Hamaguchi 
score showed 100% specificity and 91.7% sensitivity when compared with liver biopsy in NAFLD 
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patients [26]. A further limitation is the higher prevalence of females in PNPLA3MM group which 
may have determined the lower cardiometabolic risk, considering the weight that gender has in the 
Framingham score. Finally, the rather low number of patients in the PNPLA3MM group may also 
represent a limitation to draw definitive conclusions based on genetic polymorphism. 
 
 
Conclusions 
We suggest that NAFLD may not always represent the hepatic manifestation of MetS. In fact, in our 
study, patients with NAFLD carrying PNPLA3-I148M gene had a lower prevalence of MetS and 
lower cardiometabolic risk. Further studies are needed to confirm the possible role of PNPLA3 
polymorphisms to differentiate clinical phenotypes of NAFLD and  to discriminate NAFLD with 
possible metabolic and cardiovascular consequences from fatty liver at risk for liver related 
complications. 
 
Conflict of interests: All authors declare that they have no conflicts of interest. 
 
Learning points:  
 NAFLD does not always represent the hepatic manifestation of MetS 
 PNPLA3 I148M gene variant is associated with a lower prevalence of metabolic syndrome 
and lower cardiometabolic risk. 
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Table 1. Clinical and biochemical characteristics of subjects according to severity of non-
alcoholic fatty liver disease (NAFLD)  at ultrasonography 
 
 
NAFLD 
 
 
 
Mild   
(n=40) 
 
 
Moderate 
(n=90) 
 
Severe 
(n=81) 
 
p 
Gender (F/M) % 45.0/55.0 36.7/63.3 29.6/70.4 ns 
Age (yrs) 49.9 (14.6) 56.0 (11.5) 54.6 (10.4) ns 
BMI (kg/m2) 29.6 (5.1) 30.3 (5.3) 33.5 (5.3) <.001 
Waist circumference (cm) 103,5 (97,3/109,5) 105 (98/113) 113  (106/125) <.001 
Fasting plasma glucose (mg/dl) 92 (86/100,5) 97 (92,8/117,5) 107 (95/128,3) <.001 
Insulin (mU/l) 11,5 (7,7/15,5) 13 (9,3/17,9) 16,6 (12,5/24,5) <.001 
HbA1c (%) 5,4 (5,1/5,7) 5,6 (5,3/6,1) 6 (5,6/6,5) <.001 
HOMA IR 2.5 (1.6/3.7) 3.1 (2.2/4.7) 5.2 (3.1/7.3) <.001 
Total Cholesterol (mg/dl) 209 (41) 201 (40) 198 (40) ns 
Triglycerides (mg/dl) 132,5 (188,3/175/8) 138 (99,8/179) 152,5 (119,5/197,8) ns 
HDL cholesterol (mg/dl) 53 (43/60) 45,5 (39,8/60,3) 43 (38/51)  <.05 
LDL cholesterol (mg/dl) 125 (34) 121 (35) 118 (33) ns 
AST (UI/l) 19 (16/26,8) 21 (18/25) 22 (18/32) ns 
ALT (UI/l) 21 (17,3/34) 26 (20,8/40) 34 (24/45) <.05 
GT (UI/l) 23 (16,5/42,3) 21 (16/36) 32 (23,8/55) ns 
Cytokeratin 18 (mIU/ml) 169,5 (129,3/183,8) 176 (140/190) 180 (169,5/192,5) <.01 
Adiponectin (ng/ml) 10,3 (5,5/12) 8,8 (6/13,1) 6,0 (4,9/9,1) <.001 
Framingham cardiovascular 
risk score (%)* 
5 (1/14,5) 6 (3/13) 3 (9/14) ns 
*see Methods 
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Table 2. Prevalence of MetS and its clinical features in subjects with different 
severity of steatosis at liver ultrasonography. 
 
 NAFLD  
 
Mild 
(n=40) 
Moderate 
(n=90) 
Severe 
(n=81) 
p 
Metabolic Syndrome (%)* 52.5 65.2 82.3 <.01 
High blood pressure (%)* 55 78.9 88.6 <.001 
High waist circumference (%)* 70 75 91.1 <.01 
High fasting blood glucose (%)* 25 44.4 65 <.001 
High triglycerides  (%)* 40 44.4 55 ns 
Low HDL-cholesterol  (%)* 25 35.6 46.3 ns 
MetS Score** 3 (2/4) 3 (2/4) 4 (3/5) <.01 
 
*Defined according to ATPIII criteria; **see Methods 
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Table 3. Clinical and biochemical characteristics of subjects with different PNPLA3 
genotypes 
 
                                  PNPLA3 genotypes 
 
148II 
(95) 
148IM  
(86) 
148MM  
(30) 
p 
Gender (F/M) % 27.4/72.6 39.5/60.5 50/50 <.05* 
Metabolic Syndrome (%) 71.6 72.1 50 <.05* 
Age (yrs) 54 ± 11 54 ± 12.8 54.3 ± 12.1 ns 
Weight (kg) 92.2±18.1 89.0±16.5 89.8±16.2 ns 
BMI (kg/m2) 32.1±5.6 30.4±5.1 31.7±6.1 ns 
Waist circumference (cm) 110(103.5/118) 105(101/113.5) 106 (96.7/118.5) ns 
Fasting plasma glucose (mg/dl) 101 (92/110) 97 (92/121) 101 (87.5/128.2) ns 
Insulin (μU/ml) 14.1(10.7/20.2) 13.7(10.1/19.4) 11.6 (8.7/16.8) ns 
HOMA IR 3.6 (2.3/5.8) 3.5 (2.5/5.7) 2.8 (2.0/5.6) ns 
Total Cholesterol (mg/dl) 205 ± 41.9 198 ± 40.3 196.9 ± 34.3 ns 
Triglycerides (mg/dl) 157 (112/193) 141(107.7/185) 111.5(90.7/148.7) <.01* 
HDL cholesterol (mg/dl) 45 (39/53) 44 (38/56) 50.5 (43/61) ns 
AST (UI/l) 20 (17/25) 21 (18/31) 23 (17.7/27.7) ns 
ALT (UI/l) 26 (19/35) 30.5 (22/45) 30 (22.7/40.5) ns 
GT (UI/l) 28 (19/42) 28 (17/46) 22 (17.5/39.5) ns 
Cytokeratine 18 (mIU/ml) 180 (143/192) 180 (151.2/190) 170.5 (130/182.2) ns 
Adiponectin (ng/ml) 7.5 (5/11) 7.5 (5.5/12) 9.3 (4.9/13.1) ns 
Framingham cardiovascular 
risk score (%) 
9 (3/16.7) 6 (2/13) 4 (2/8.2) <.01* 
Hamaguchi score 4 (3/5) 4 (3/5) 4 (3/5) ns 
MetS score** 4 (2/5) 3 (2/4) 2 (1,75/4) <.01* 
 
*148MM vs 148II; **see Methods 
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Table 4. Multiple logistic analysis of independent predictors of metabolic 
syndrome in 211 subjects with non-alcoholic fatty liver disease.   
 
 B S.E. P. O.R. 95,0% C.I. for O.R. 
      Lower Upper 
  Age .062 .015 .000 1.064 1.032 1.096 
  PNPLA3.148MM -1.195 .460 .009 .303 .123 .746 
  HOMA-IR .267 .083 .001 1.306 1.110 1.538 
  Constant -3.234 .858 .000 .039   
 
Variables entered on step 1: age, gender, PNPLA3.148MM, Hamaguchi score, HOMA-IR, serum ALT 
serum adiponectin, positive family history for diabetes and cardiovascular disease. 
 
 
 
Highlights:  
1. Non-alcoholic fatty liver disease (NAFLD) is usually considered the hepatic consequence of the 
metabolic syndrome. 
 
2. Polymorphisms of patatin-like phospholipase domain-containing protein 3 (PNPLA3)  gene may 
predispose to NAFLD and its progression. 
 
3. We evaluated whether PNPLA3 gene variants may predict different clinical phenotypes of 
NAFLD patients. 
 
4. Patients with PNPLA3 I148M gene variant have lower prevalence of  metabolic syndrome and 
lower cardiometabolic risk. 
Highlights (for review)
